Tecvayli (teclistamab-cqyv) / Genmab, J&J  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecvayli (teclistamab-cqyv) / Genmab, J&J
MajesTEC-1, NCT03145181 / 2016-002122-36: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Checkmark Results for relapsed/recurrent multiple myeloma at ASCO 2021
Jun 2021 - Jun 2021: Results for relapsed/recurrent multiple myeloma at ASCO 2021
Checkmark Presentation of data from trial in 1L r/r multiple myeloma at ASCO 2020
May 2020 - May 2020: Presentation of data from trial in 1L r/r multiple myeloma at ASCO 2020
Recruiting
1
282
Europe, US
Teclistamab (IV), JNJ-64007957, Teclistamab(SC)
Janssen Research & Development, LLC, Janssen Research & Development, LLC, JANSSEN CILAG SPA
Hematological Malignancies
11/21
07/26
MajesTEC-10, NCT06425991: A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
100
US, RoW
Teclistamab, JNJ-64007957
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
07/25
01/27
MajesTEC-2, NCT04722146: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Checkmark MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Dec 2022 - Dec 2022: MajesTEC-2 study of Tecvayli combo Darzalex Faspro and lenalidomide
Active, not recruiting
1
140
Europe, US, RoW
Teclistamab, JNJ-64007957, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat
Janssen Research & Development, LLC
Multiple Myeloma
10/24
02/25
TRIMM-2, NCT04108195: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Active, not recruiting
1
290
Europe, Canada, US
Daratumumab, JNJ-54767414, Darzalex, Talquetamab, JNJ-64407564, Teclistamab, JNJ-64007957, Pomalidomide
Janssen Research & Development, LLC
Multiple Myeloma
09/24
08/25
TRIMM-3, NCT05338775: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
152
Europe, US
Talquetamab, Teclistamab, PD-1 Inhibitor
Janssen Research & Development, LLC
Relapsed/ Refractory Multiple Myeloma
09/24
11/25

Download Options